胸膜腔注射尿激酶治疗结核性胸膜炎疗效分析

目的 观察胸膜腔注射尿激酶对结核性渗出性胸膜炎的治疗效果。方法91例结核性胸膜炎并胸腔积液患者随机分为治疗组（40例）和对照组（51例），2组均予以全身化疗及抗炎治疗，治疗组在此基础上加用尿激酶于胸膜腔内注射。观察2组患者胸水量、胸水吸收时间及治疗效果。结果胸水15d以内吸收者，治疗组72．5％（29／40），对照组为37．3％（19／51）；胸膜肥厚粘连发生率，治疗组35．0％（14／40），对照组为72．5％（37／51）。2组比较差异有统计学意义（P〈0．05）。结论胸膜腔注射尿激酶治疗结核性渗出性胸膜炎有较大的临床应用价值。

Analysis on the effect of intrapleural injection with urokinase in treatment for tuberculous pleurisy

Objective To observe the effect of intrapleural injection with urokinase for tuberculous exudative pleurisy. Methods 91 cases with tuberculous pleurisy were divided into the therapy group（ n = 40） and the control group（ n = 51 ）. After routine applying antituberculosis drugs and chemotherapy , urokinase was injected into pleural cavity in the therapy group. Then the amount of pleural fluid, the time of pleural effusion absorption and the effect were observed. Results Absorption of pleural fluid within 15 days ,in the treatment group and the control group, was 72.5% （29/40） and 37.3% （19/51）. The incidence of pleural thickening adhesion was 35.0% （14/40） in treatment group and 72.5% （37/51） in the control group. There is obvious difference between two groups （ P 〈 0.05 ）. Conclusion Intrapleural injection with urokinase has greater clinical value in the treatment of tuberculous exudative pleurisy.